SEARCH

SEARCH BY CITATION

References

  • 1
    Bray, G. A., Blackburn, G. L., Ferguson, J. M., et al (1999) Sibutramine produces dose-related weight loss. Obes Res. 7: 189198.
  • 2
    James, W. P., Astrup, A., Finer, N., et al (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial: STORM Study Group. Lancet. 356: 21192125.
  • 3
    Smith, I. G., Goulder, M. A., Behalf of the members of the Sibutramine Clinical Study 1047 Team. (2001) Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 50: 505512.
  • 4
    Wirth, A., Krause, J. (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 286: 13311339.
  • 5
    Apfelbaum, M., Vague, P., Ziegler, O., Hanotin, C., Thomas, F., Leutenegger, E. (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 106: 179184.
  • 6
    McMahon, F. G., Fujioka, K., Singh, B. N., et al (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 160: 21852191.
  • 7
    Fujioka, K., Seaton, T. B., Rowe, E., et al (2000) Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diab Obes Metab. 2: 175187.
  • 8
    Hadvary, P., Lengsfield, H., Wolfer, H. (1998) Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J. 256: 357361.
  • 9
    Zhi, J., Melia, A. T., Funk, C., et al (1996) Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol. 36: 10061011.
  • 10
    Zhi, J., Melia, A. T., Guerciolini, R., et al (1994) Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 56: 8285.
  • 11
    Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G. (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res. 8: 4961.
  • 12
    Sjöström, L., Rissanen, A., Andersen, T., et al (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet. 352: 167172.
  • 13
    Davidson, M. H., Hauptman, J., DiGirolamo, M., et al (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 281: 235242.
  • 14
    Finer, N., James, W. P., Kopelman, P. G., Lean, M. E., Williams, G. (2000) One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 24: 306313.
  • 15
    Hauptman, J., Lucas, C., Boldrin, M. N., Collins, H., Segal, KR. (2000) Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 9: 160167.
  • 16
    Torgerson, J. S., Hauptman, J., Boldrin, M. N., Sjöström, L. (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 27: 155161.
  • 17
    Hollander, P. A., Elbein, S. C., Hirsch, I. B., et al (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 21: 12881294.
  • 18
    Miles, J. M., Leiter, L., Hollander, P., et al (2002) Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 25: 11231128.
  • 19
    Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., et al (2002) Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year, randomized controlled trial. Diabetes Care. 25: 10331041.
  • 20
    Mittendorfer, B., Ostlund, R. E., Jr, Patterson, B. W., Klein, S. (2001) Orlistat inhibits dietary cholesterol absorption. Obes Res. 9: 599604.
  • 21
    Schnetzler, B., Kondo-Oestreicher, M., Vala, D., Khatchatourian, G., Faidutti, B. (2000) Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation. 70: 15401541.
  • 22
    Colman, E., Fossler, M. (2000) Reduction in blood cyclosporin concentrations by orlistat. N Engl J Med. 342: 11411142.
  • 23
    Le Beller, C., Bezie, Y., Chabatte, C., Guillemain, R., Amrein, C., Billaud, EM. (2000) Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation. 70: 15411542.
  • 24
    Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Prus-Wisniewski, R., Steinberg, C. (2001) Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 161: 218227.